The Best Method for CMV Prevention in High-risk Kidney Transplant Recipients? Either, per National Norwegian Transplant Database: Commentary on Blom et al, Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management.

Kotton, CN

In: Transplantation, Jg. 107 (2023-08-01), Heft 8, S. 1671-1672

academicJournal

Titel:	The Best Method for CMV Prevention in High-risk Kidney Transplant Recipients? Either, per National Norwegian Transplant Database: Commentary on Blom et al, Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management.
Autor/in / Beteiligte Person:	Kotton, CN
Zeitschrift:	Transplantation, Jg. 107 (2023-08-01), Heft 8, S. 1671-1672
Veröffentlichung:	Hagerstown, MD : Lippincott Williams & Wilkins ; <i>Original Publication</i>: Baltimore, Williams & Wilkins., 2023
Medientyp:	academicJournal
ISSN:	1534-6080 (electronic)
DOI:	10.1097/TP.0000000000004616
Schlagwort:	Humans Cytomegalovirus Antiviral Agents therapeutic use Valganciclovir therapeutic use Ganciclovir therapeutic use Transplant Recipients Kidney Transplantation adverse effects Cytomegalovirus Infections diagnosis Cytomegalovirus Infections epidemiology Cytomegalovirus Infections prevention & control
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Comment Language: English [Transplantation] 2023 Aug 01; Vol. 107 (8), pp. 1671-1672. <i>Date of Electronic Publication: </i>2023 May 22. MeSH Terms: Kidney Transplantation* / adverse effects ; Cytomegalovirus Infections* / diagnosis ; Cytomegalovirus Infections* / epidemiology ; Cytomegalovirus Infections* / prevention & control ; Humans ; Cytomegalovirus ; Antiviral Agents / therapeutic use ; Valganciclovir / therapeutic use ; Ganciclovir / therapeutic use ; Transplant Recipients Comments: Comment on: Transplantation. 2023 Aug 1;107(8):1846-1853. (PMID: 37211633) References: Blom KB. Cytomegalovirus high-risk kidney transplant recipients show no difference in long-term outcomes following preemptive versus prophylactic management. Transplantation. 2023;107:1846–1853. ; Kotton CN, Kumar D, Caliendo AM, et al.; The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102:900–931. ; Ljungman P, Boeckh M, Hirsch HH, et al.; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91. ; Meesing A, Razonable RR. Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation. Open Forum Infect Dis. 2018;5:ofy230. ; Kumar D, Chin-Hong P, Kayler L, et al. A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. Am J Transplant. 2019;19:2505–2516. ; Hall VG, Humar A, Kumar D. Utility of cytomegalovirus cell-mediated immunity assays in solid organ transplantation. J Clin Microbiol. 2022;60:e0171621. ; Magua W, Johnson AC, Karadkhele GM, et al. Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high-risk cytomegalovirus serostatus kidney transplant recipients. Transpl Infect Dis. 2022;24:e13983. ; Khawaja F, Spallone A, Kotton CN, et al. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. Clin Microbiol Infect. 2023;29:44–50. ; Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90:1427–1431. ; Balfour HH Jr. Cytomegalovirus: the troll of transplantation. Arch Intern Med. 1979;139:279–280. Substance Nomenclature: 0 (Antiviral Agents) ; GCU97FKN3R (Valganciclovir) ; P9G3CKZ4P5 (Ganciclovir) Entry Date(s): Date Created: 20230522 Date Completed: 20230724 Latest Revision: 20230809 Update Code: 20240514

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.